Thomas W. Flaig
University of Colorado Hospital(US)The Medical Center of Aurora(US)University of Colorado Health(US)University of Colorado Cancer Center(US)University of Colorado Anschutz Medical Campus(US)University of Colorado Denver(US)
Publications by Year
Research Areas
Bladder and Urothelial Cancer Treatments, Prostate Cancer Treatment and Research, Urinary and Genital Oncology Studies, Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment
Most-Cited Works
- → Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy(2012)4,537 cited
- → Abiraterone and Increased Survival in Metastatic Prostate Cancer(2011)4,364 cited
- → Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy(2012)2,764 cited
- → Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study(2015)1,334 cited
- → Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology(2020)623 cited
- → Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial